Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions
Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions: Dosimetric and Clinical Outcomes
National University Hospital, Singapore
56 participants
Jun 26, 2023
INTERVENTIONAL
Conditions
Summary
Aim To determine the feasibility and safety of 3 fractions of high dose rate (HDR) brachytherapy with interstitial needles for cervical cancer in the outpatient setting Primary objective To determine the clinical outcome (2-yr local control rate, loco-regional control rate, progression free survival and overall survival) Secondary objective To determine the long-term toxicities of this regimen based on CTCAE v5
Eligibility
Inclusion Criteria7
- years old and above
- Histologically proven squamous cell carcinoma, adenocarcinoma, adenosquamous or poorly differentiated cervical cancer
- Clinically or radiologically stage IB - IVA cervical cancer based on TNM 8th Edition
- ECOG performance status 0, 1, or 2
- To complete external beam radiotherapy and brachytherapy in NUH
- Written, voluntary informed consent
- Patients must be accessible for follow up and management in NUH
Exclusion Criteria2
- Post operative cervical cancer cases
- Pregnant or breastfeeding women
Interventions
The 3 fractions of HDR brachytherapy may be delivered in the following ways: Option 1: 3 insertions over 2 non-consecutive days: Option 2: 3 insertions over 3 non-consecutive days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06284031